ScreenerHero

XNCRXencor, Inc.

NAS · US · Healthcare · Biotechnology · xencor.com
27.80USD+1.02%Mkt Cap: 2.07B $P/E: —

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat pat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.07B $
Enterprise Value1.72B $
Revenue (TTM)104.97M $
Gross Profit-150.79M $
Net Income (TTM)-91.92M $
Revenue/Share1.399 USD
Last Price27.80 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees260
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.74
PEG—
EV/EBITDA-8.36
EV/Revenue16.40
P/S19.12
P/B3.88
EPS (TTM)-2.12
EPS (Forward)-3.49
52W Range
7.13098% of range28.16
52W High28.16 USD
52W Low7.130 USD
Profitability
Gross Margin-143.65%
Oper. Margin-72.37%
EBITDA Margin-196.15%
Profit Margin-73.20%
ROE-14.46%
ROA-10.50%
Growth
Revenue Growth17.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-135.12M $
CapEx (TTM)3.15M $
FCF Margin-90.06%
FCF Yield-4.57%
Net Debt-286.34M $
Net Debt/EBITDA1.39
Balance Sheet
Debt/Equity0.30
Current Ratio6.39
Quick Ratio6.09
Book Value/Sh6.962 USD
Cash/Share6.139 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)29.00 USD
Upside (mean)+4.3%
Target Range14.00 USD – 44.00 USD
$14.00+4.3% to mean$44.00
# Analysts12
Ownership
Shares Out.74.35M
Float54.25M
Insiders1.22%
Institutions114.77%
Short Interest
Short Ratio10.3d
Short % Float21.64%
Short % Out.15.26%
Shares Short11.34M
Short (prev mo.)11.51M
Technical
SMA 5017.84 (+55.9%)
SMA 20014.40 (+93.0%)
Beta0.84
S&P 52W Chg18.16%
Avg Vol (30d)1.06M
Avg Vol (10d)1.35M
Technical Indicators
RSI (14)82.9
MACD2.3457
MACD Signal1.8430
MACD Hist.+0.5027
BB Upper26.57 USD
BB Middle21.58 USD
BB Lower16.59 USD
BB Width46.25%
ATR (14)1.403 USD
Vol Ratio (20d)0.67x